Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

M1 > Biochemisty of Drugs as Enzyme Inactivators > Flashcards

Biochemisty of Drugs as Enzyme Inactivators Flashcards

1
Q

A mechanism-based enzyme inactivator is

A

an unreactive compound that bears a structural similarity to the substrate or product for a specific enzyme.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Irreversible inhibitor bond

A

covalent bond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

inactivators that does not form a covalent bond to the enzyme

A

methotrexate and allopurinol bind so tightly without covalent modification

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The advantage of mechanism-based enzyme inactivators lies in the fact that these compounds are

A

unreactive, thus limiting toxicity and side effects

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

compounds used to protect penicillin and cephalosporins against bacterial degradation (inactivate bacterial β-lactamases)

A

Clavulanic acid, sulbactam, and tazobactam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

agent reduce high levels of uric acid in gout (inactivates xanthine oxidase)

A

Allopurinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

an antiparkinson agent (inactivates MAO-B)

A

L-deprenyl

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

an anticonvulsant (antiseizure) agent (inactivates GABA-T)

A

Vigabatrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

a chemotherapy agent (inactivates DHFR)

A

Methotrexate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

an antineoplastic agent for CML and GIST, (inactivates Bcr-Abl p210, c-KIT and PDGFR tyrosine kinases)

A

Imatinib mesylate

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

affects NO in pulmonary hypertension (inactivates PDE5)

A

Sildenafil

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

anticonvulsant (inactivates HDAC1)

A

Valproic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

cancer chemotherapy (Proteosome Inhibitor)

A

Bortezomib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

These inhibitors contain the β-lactam ring, which disguises its role as irreversible inhibitors. The attack by the enzyme on clavulanic acid is the same step as with penicillin (i.e. an acylation reaction). This is followed by a second and lethal step with the inhibitor, the β-elimination, which does not dissociate it from the enzyme.

A

β-Lactamase Inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Clinically, the β-lactamase inactivators are used in combination with the _______ for the treatment of __________. Combinations include:

A

pencillins; penicillin-resistant bacterial infections. amoxicillin/clavulanic acid (Augmentin) ticarcillin/clavulanic acid (Timentin) ampicillin/sulbactam (Unasyn) piperacillin/tazobactam (Zosyn)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Uric acid (UA) in humans is formed by the

A

xanthine oxidase-catalyzed oxidation of hypoxanthine and xanthine, derived from the hydrolysis of adenine and guanine respectively.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

disease with UA in joints

A

Gout

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

acute leukemia with high cell turnover (UA breakdown product from DNA). Give allopurinol and hydration during chemotherapy.

A

Cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

inhibits the biosynthesis of uric acid

A

allopurinol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Allopurinol is oxidized by

A

xanthine oxidase to oxypurinol with the associated reduction of Mo(VI) cofactor to Mo (IV) (the molybdenum pterin active site).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

oxypurinol (alloxanthine), is a potent, tight-binding inhibitor of the enzyme, but only when it is in the _____ state

A

reduced

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

an anti-parkinson agent

A

L-deprenyl (selegiline)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

a degenerative neurological disease affecting more than a 500,000 in US. Characterized by chronic progressive motor dysfunction resulting in severe “pill rolling” tremors, rigidity, and akinesia.

A

Parkinson’s disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Parkinson’s disease arise from the degeneration _______ of and a marked reduction in the concentration of the pyridoxal-5’-phosphate-dependent aromatic ________ , the enzyme that catalyzes the conversion of ________.

A

dopaminergic neurons in the substantia nigra; L-amino acid decarboxylase; L-dopa to the inhibitory neurotransmitter dopamine.

25
Q

metabolized (degraded) primarily by monoamine oxidase B (MAO-B) in humans

A

dopamine

26
Q

Parkinson’s disease =

A

reduction in the brain dopamine concentration (substantia nigra)

27
Q

effective in increasing the dopamine concentration and thus treat the disease (by L-deprenyl

A

Selective inactivation of MAO-B

28
Q

an anticonvulsant (anti-seizure) agent

A

Vigabatrin

29
Q

any central nervous system disease characterized by recurring convulsive seizures occurring in 0.5-1% of the world population

A

Epilepsy (seizure disorder)

30
Q

when no cause for the seizure is known

A

primary or idiopathic

31
Q

when the etiology of seizure has been identified

A

secondary or symptomatic

32
Q

Symptomatic epilepsy can result from specific diseases or secondary causes

A

brain tumors, syphilis, cerebral arteriosclerosis, multiple sclerosis, Buerger’s disease, Pick’s disease, Alzheimer’s disease, heat-stroke, acute intoxication, lead poisoning, head trauma, vitamin B-6 deficiency, hypoglycemia, and labor.

33
Q

seizures occur when there is an imbalance in 2 principal neurotransmitters in the brain, _________ and _________

A

L-glutamic acid, an excitatory neurotransmitter, and gamma-aminobutyric acid (GABA)

34
Q

L-glutamic acid, ________neurotransmitter

A

an excitatory

35
Q

gamma-aminobutyric acid (GABA), __________ neurotransmitter.

A

an inhibitory

36
Q

GABA concentration is regulated ________

A

by 2 pyridoxal 5’-phosphate (PLP)-dependent enzymes.

37
Q

2 Pyridoxal 5’-phosphate dependent enzymes

A

L-glutamic acid decarboxylase (GAD, glutamate decarboxylase): converts glutamate → GABA GABA aminotransferase (GABA-T, 4-aminobutyrate aminotransferase): degrades GABA → succinic semialdehyde which is subsequently converted into succinic acid by the enzyme succinic semialdehyde dehydrogenase (SSADH, succinate semialdehyde dehydrogenase) √ (vigabatrin)

38
Q

Below a set threshold concentration of GABA level in the brain, ______ occur

A

seizures Low (inhibitory) GABA = seizure discharges

39
Q

GABA system dysfunction has been implicated in the symptoms associated with _______

A

epilepsy,Huntington’s disease, Parkinson’s disease, and tardive dyskinesia.

40
Q

if GABA is given orally, there is no anticonvulsant effect. Why?

A

GABA, being polar, cannot cross the blood-brain barrier

41
Q

the enzyme that catalyzes the degeneration of GABA

A

GABA-T

42
Q

Enhancing GABA (inhibitory) in brain of addicts may control ________

A

drug cravings

43
Q

Methotrexate Mechanism of Action

A

Enzyme DHFR is the 1º site of action. MTX inhibits formation of THF (tetrahydrofolate), causing an intracellular deficiency of folate coenzymes and accumulation of the toxic inhibitory substrate, DHF polyglutamate (dihydrofolate). The one carbon transfer reactions for purine and thymidylate synthesis cease (no deoxythymidilate or dTMP), interrupting DNA and RNA synthesis.

44
Q

MTX Mechanisms of Resistance

A

Decreased drug transport Altered DHFR (mutation) Decreased polyglutamate formation Increased levels of DHFR

45
Q

Methotrexate Therapeutic Uses

A

Inflammatory Diseases (rheumatology): psoriasis, rheumatoid arthritis, SLE (lupus). Oncology: acute lymphoblastic leukemia, meningeal leukemia, choriocarcinoma, osteosarcoma, mycosis fungoides, Burkitt’s and non-Hodgkin’s lymphomas, cancers of the breast, head and neck, ovary, and bladder high dose MTX – followed by leucovorin rescue (bypassing inhibition to minimize side effects)

46
Q

Methotrexate Side Effects

A

Wide range of activity in all dosages (oral, IV and high dose). Acute Side Effects: nausea, vomiting, diarrhea, fever, hepatic necrosis, allergy Dose Limiting Toxicity: Oral and GI ulceration (mucositis), bone marrow suppression, pulmonary fibrosis Delayed Toxicities: hepatic/renal toxicity, encephalopathy, conjunctivitis, alopecia, depigmentation

47
Q

Methotrexate Toxicity Treatment

A

Bone marrow suppression Rescue with leucovorin (folinic acid) Essential after high dose MTX Nephrotoxic give sodium bicarbonate to alkalinize the urine Effective killing of rapidly dividing cancer cells; also epithelial, hair follicle and BM stem

48
Q

the 571st signal transduction inhibitor which Novartis worked on to produce a tyrosine kinase inhibitor which works specifically on the intracellular domain of CD117, the c-KIT receptor

A

Imatinib

49
Q

Imatinib revolutionized the treatment of _______ and _______

A

chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) tumors

50
Q

caused by immortalization of cellular population due to the Philadelphia chromosome which produces the bcr-abl fusion protein by a balanced translocation between the long arms of chromosomes 9 and 22. T(9,22)

A

CML (chronic myelogenous leukemia)

51
Q

imatinib inhibits

A

Bcr-Abl tyrosine kinase, the constitutive abnormally phosphorylated gene product of the Philadelphia chromosome in CML

52
Q

Inhibition blocks proliferation and induces apoptosis in Bcr-Abl positive cell lines as well as in

A

fresh leukemic cells in Philadelphia chromosome positive cell lines

53
Q

Imatinib blocks

A

ATP binding

54
Q

is a cancer with upregulated c-kit

A

Gastrointestinal stromal tumor (GIST)

55
Q

Imatinib also inhibits tyrosine kinases for

A

platelet derived growth factor (PDGF), stem cell factor (SCF), c-kit, and events mediated by PDGF and SCF

56
Q

Tyrosine kinase inhibitors (TKIs) like imatinib induce

A

sustained responses in both hematologic and solid malignancies

57
Q

associated with fewest secondary (or off target side effects)

A

BCR-ABL1 inhibition

58
Q
A

M1 (48 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions